Stage II Seminoma: Why Chemotherapy Should Remain a Standard

Naoun, Natacha; Bernard‐Tessier, Alice; Fizazi, Karim

doi:10.1016/j.euros.2022.06.010

Cited by 2 publications

(2 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The PRIMETEST trial (n ¼ 33, median follow-up 32 months) achieved 2-year 72% RFS and 70% PFS after primary open or robotic RPLND for CS IIA/B disease, falling short of its 30% PFS endpoint. The number of total chemotherapy cycles was reduced from 99 to 30 in comparison to the standard regimen [21,22]. Similarly, the COTRIMS trial (n ¼ 30, median follow-up 22 months) resulted in three recurrences by 9 months post-RPLND, all successfully salvaged with chemotherapy [23].…”

Section: Clinical Stage II Seminomamentioning

confidence: 99%

Testicular cancer with small metastatic burden: optimal approach in 2024

Yuen,

Pandit,

Puri

et al. 2024

Current Opinion in Urology

View full text Add to dashboard Cite

Purpose of review Recent advancements in the management of clinical stage II (CS II) testicular cancer have transformed it into a predominantly curable condition. This success in treatment advancements has markedly extended patient survival. However, these treatments carry risks and morbidities, which is important to consider given the disease's impact on young men and the emerging understanding of long-term treatment consequences. Recent findings Emerging data support primary retroperitoneal lymph node dissection (RPLND) for select CS II seminoma patients, with similar short-term outcomes to chemotherapy but less treatment intensity. Recent studies have also challenged the reflexive use of adjuvant chemotherapy for pathologic node-positive disease, as growing evidence shows low relapse rates regardless of nodal stage. Furthermore, novel biomarkers like circulating serum microRNA-371a-3p levels can help predict the presence of viable germ cell tumor at time of RPLND. Summary Advances in risk stratification and therapy enable personalized de-escalation approaches for oligometastatic testicular cancer, optimizing survivorship. Upfront RPLND, reassessing adjuvant systemic therapy for RPLND pN+ disease, and novel biomarkers will shape precision treatment to achieve high cure rates with excellent quality of life. Ongoing trials of reduced-intensity regimens, accurate prognostic models, improved surgical strategy, and emerging biomarkers represent the next frontier in tailored curative therapy.

show abstract

Section: Clinical Stage II Seminomamentioning

confidence: 99%

Testicular cancer with small metastatic burden: optimal approach in 2024

Yuen,

Pandit,

Puri

et al. 2024

Current Opinion in Urology

View full text Add to dashboard Cite

show abstract

“…The treatment methods vary according to the tumor stage, with radiotherapy and chemotherapy typically administered for metastatic seminoma, while chemotherapy is preferred for larger metastatic tumors (4). However, chemotherapy may not clear the entire tumor, resulting in residual lesions in some patients, and can also cause long-term toxicity and side effects including thromboembolic and cardiovascular diseases (5)(6)(7), neurological sequelae (such as hearing impairment, neuropathy and renal damage) and secondary malignant tumors (8,9). Therefore, there is currently some controversy over the choice of treatment options.…”

Section: Introductionmentioning

confidence: 99%

Iodine‑125 seeds combined with carboplatin in the treatment of retroperitoneal metastatic seminoma: A case report and literature review

Ran,

Liu,

Jiang

2024

Oncol Lett

View full text Add to dashboard Cite

Testicular seminoma is a relatively rare malignant tumor, with the most common site of recurrence and metastasis being the retroperitoneal lymph nodes. Since seminoma is highly sensitive to radiotherapy and chemotherapy, even if it metastasizes, its cure rate is still >95%. However, the long-term toxicity and side effects of radiotherapy and chemotherapy cannot be ignored. Iodine-125 seeds represent a low-energy radioactive source that kills tumor cells while protecting the surrounding normal tissues, and brachytherapy using iodine-125 seeds has been widely used for the treatment of various malignancies. In addition, carboplatin can be used as an alternative to cisplatin-based combination chemotherapy to reduce the incidence of pulmonary toxicity, neurological damage and renal toxicity. In the present study, a case in which iodine-125 seeds were implanted for the treatment of retroperitoneal metastatic seminoma is reported. The patient was diagnosed with postoperative recurrence of seminoma that metastasized to the retroperitoneal lymph nodes. Since the tumor was large and surrounded blood vessels, surgical intervention and external radiotherapy were not considered. Moreover, considering the potential long-term toxic side effects of standard chemotherapy, a treatment plan for the patient using iodine-125 seed implantation combined with carboplatin (AUC7) therapy was finally formulated. No disease recurrence or toxic reactions occurred during the 3-year follow-up after treatment. The present case therefore demonstrated the antitumor efficacy and reduced toxicity of iodine-125 seeds combined with carboplatin for treating seminoma.

show abstract

Stage II Seminoma: Why Chemotherapy Should Remain a Standard

Cited by 2 publications

References 12 publications

Testicular cancer with small metastatic burden: optimal approach in 2024

Testicular cancer with small metastatic burden: optimal approach in 2024

Iodine‑125 seeds combined with carboplatin in the treatment of retroperitoneal metastatic seminoma: A case report and literature review

Contact Info

Product

Resources

About